GENENTECH INC

THIS PROJECT FOCUSES ON ADDRESSING CRITICAL CHALLENGES IN THE DESIGN AND ANALYSIS OF HYBRID RANDOMIZED CONTROLLED TRIALS (RCTS) IN LONGITUDINAL SETTINGS. THE FIRST GOAL IS TO DEVELOP CAUSAL METHODOLOGIES FOR MANAGING DIVERSE MISSING DATA PATTERNS IN

MOD SOW FOR CLINS 0007, 0010, AND 0011 LEPB NONCLINICAL AND CLINICAL DEVELOPMENT, CLIN 0012 TRAUMATIC BRAIN INJURY (TBI) DIAGNOSTICS AND MONITORING. ADD FUNDING AND MODIFY SOW. MODIFY ARTICLE VI (COST SHARING): THE TOTAL VALUE OF COMMITTED FUNDS FROM

THE PURPOSES OF THIS MODIFICATION ARE TO: 1. CLIN 0011 - LEPB NONCLINICAL AND CLINICAL DEVELOPMENT: ADD FUNDING OF $11,500,000.00 AND MODIFY THE STATEMENT OF WORK (SOW) TO SUPPORT CLINICAL AND NON-CLINICAL PHARMACOLOGY, RESISTANCE, AND SUSCEPTIBILI

1) CLIN 0003, ALTEPLASE SULFUR MUSTARD INDICATION. EXTEND THE PERIOD OF PERFORMANCE. 2) CLIN 0011 LEPB NONCLINICAL AND CLINICAL DEVELOPMENT. ADD SUPPLEMENTAL WITHOUT MODIFYING THE STATEMENT OF WORK. 3) CLARIFY COMPOSITION OF THE JOC AND ITS VOTERS.

EXERCISE CLIN 0012 FOR TBI DIAGNOSTIC AND MONITORING AND EXTEND CLIN 0009 COVASTIL PERIOD OF PERFORMANCE.

DE-OBLIGATE CANCELING FUNDS FROM CLIN 0003.

SUPPLEMENTAL FUNDING, REVISE OTTR, AND REVISE STATEMENT OF WORK.

GENENTECH UMBRELLA AGREEMENT

GENENTECH UMBRELLA AGREEMENT